laurabbook@gmail.com

*March 2022* This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.

*February 2022* Open Questions Around First-Line Treatment for EGFR Mutant Lung Cancers, Dr Helena Yu, presenter Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury,…

*January 2022* Highlights: p53 and Rb alterations are confirmed as predisposing to SCLC transformation in EGFR- LUAD. Paired EGFR-LUAD/SCLC samples showed diverse clonal evolution patterns. TERT amplification is an acquired event during EGFR-LUAD to SCLC transformation. Introduction Among the different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs)…

*March 2022* Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial FDA Grants Breakthrough Therapy Designation to DZD9008 for EGFR Exon20Ins-Positive NSCLC

*January 2022* Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations. Osimertinib (Tagrisso) was shown to be a durable treatment for patients with central nervous system (CNS) metastasis who had non-small…

*January 2022* Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. We conducted a systematic review to investigate the available data on this patients’ subgroup. Overall, we found a high heterogeneity in the incidence of compound mutations (4–26% of…

*January 2022* Highlights Clonal architecture of molecular alterations at the cellular level depicts cancer cell adaptation during targeted therapy. Single cell sequencing from patient biopsies revealed the co-existence of two driver alterations within single cancer cells. Pharmacological evaluation in patient derived models asserts the need of simultaneous inhibition of each driver. Read…

*January 2022* Two expert analyses appearing in the same issue of the Journal of Thoracic Oncology arrive at opposite conclusions regarding the value for metastatic non–small cell lung cancer (mNSCLC) of combining first-generation endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with either chemotherapy or vascular EGF (VEGF) monoclonal…